Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Clinical Trials Referral Office
- Phone Number: 855-776-0015
- Email: mayocliniccancerstudies@mayo.edu
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic
-
Contact:
- Clinical Trials Referral Office
- Phone Number: 855-776-0015
-
Principal Investigator:
- Nadia N. Laack, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Treated with photon/proton at Mayo Clinic Rochester in Radiation Oncology
- Radiation therapy for curative intent
Exclusion Criteria:
None
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
analyze acute and late toxicities using CTCAE 4.03
Time Frame: Patients will be followed for the duration of their life, an expected average of 20 years
|
Patients will be followed for the duration of their life, an expected average of 20 years
|
|
analyze quality of life using LASA-3 and FACT-E
Time Frame: Patients will be followed for the duration of their life, an expected average of 20 years
|
Patients will be followed for the duration of their life, an expected average of 20 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
analyze local control through tumor assessments
Time Frame: Patients will be followed for the duration of their life, an expected average of 20 years
|
Patients will be followed for the duration of their life, an expected average of 20 years
|
|
analyze survival by contacting patient and EMR (electronic medical record) review
Time Frame: Patients will be followed for the duration of their life, an expected average of 20 years
|
Patients will be followed for the duration of their life, an expected average of 20 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Nadia N. Laack, MD, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 15-000136
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumors
-
NCT03739827RecruitingSolid Tumor | Refractory Solid Tumors | Malignant Solid Tumors | Other Neoplasms Solid Tumors | Pediatric Solid Tumor
-
NCT06916442Not yet recruitingSolid Tumors, Adult | PET/CT | Solid Tumors, Advanced Solid Tumors
-
NCT05836324RecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid Tumors
-
NCT06873789Active, not recruitingAdvanced Solid Tumors | Solid Tumors | Metastatic Solid Tumors
-
NCT07589530RecruitingAdvanced Solid Tumors | Metastatic Solid Tumors | TROP2-Expressing Solid Tumors
-
NCT07215637RecruitingAdvanced Solid Tumors | Metastatic Solid Tumors
-
NCT00858377CompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
NCT00974896CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
NCT05494918CompletedAdvanced Solid Tumors | Metastatic Solid Tumors
-
NCT02596503CompletedRefractory Solid Tumors | Relapsed Solid Tumors